Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety of Dynepo in CKD Anemia
NCT00514813Phase 4Terminated
- Sponsor
- Takeda
- Start
- Jun 2007
- Primary completion
- Jul 2008
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of epoetin delta in anemia, sponsored by Takeda. Primary endpoint: Rate of Emergence of Treatment Emergent Adverse Events at 2 years. Started Jun 2007; status: terminated.
02
Drugs
epoetin delta
03
Conditions
anemia
Beyond the preview
Go deeper on NCT00514813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00514813.